Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients With Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel

PLoS ONE- United States

doi 10.1371/journal.pone.0119681

Full Text

Abstract

Available in

Date

Authors

Publisher

Public Library of Science (PLoS)

Related search

Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients With Multiple Sclerosis

PLoS ONE
Multidisciplinary
2014English

Evaluating Biomarkers of Neuronal Degeneration and Neuroinflammation in CSF of Patients With Multiple Sclerosis–osteopontin as a Potential Marker of Clinical Severity

Journal of the Neurological Sciences
Neurology
2013English

Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis

Frontiers in Immunology
AllergyImmunology
2016English

Diffusion Tensor-Mri Evidence for Extra-Axonal Neuronal Degeneration in Caudate and Thalamic Nuclei of Patients With Multiple Sclerosis

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2012English

Role of Interlekin-35 as a Biomarker in Patients With Newly Diagnosed Hashimoto’s Thyroiditis

Endocrine Regulations
EndocrinologyMetabolismDiabetes
2016English

CSF Β-Amyloid Predicts Prognosis in Patients With Multiple Sclerosis

Multiple Sclerosis
Neurology
2018English

Serum Metallothionein in Newly Diagnosed Patients With Childhood Solid Tumours.

Acta Biochimica Polonica
BiochemistryGeneticsMolecular Biology
2010English

Circulating miR-150 in CSF Is a Novel Candidate Biomarker for Multiple Sclerosis

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Serum Levels of OPG, RANKL and RANKL/OPG Ratios in Newly-Diagnosed Patients With Multiple Myeloma. Clinical Correlations

Haematologica
Hematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy